Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

ONTX was downgraded by Zacks.com  from a “acquire” score to a “hold” ranking in a research note provided to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on uncovering and creating small molecule medicine prospects to treat cancer cells. The Company‘s items under different phases of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research experts likewise just recently commented on the firm. Noble Financial editioned a “purchase” rating and released a $11.00 price purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and established a “get” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day moving ordinary price of $2.90 as well as a two-hundred day moving average price of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly profits outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) incomes per share for the quarter, topping analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as a negative web margin of 8,294.27%. The company had earnings of $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Throughout the exact same quarter in the previous year, the company published ($ 0.45) EPS. En masse, research experts anticipate that Onconova Therapeutics will certainly post -1.18 EPS for the current year.

A number of hedge funds have recently dealt shares of ONTX. GSA Funding Allies LLP bought a new setting in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Administration LP bought a new position in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC got a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a new setting in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as various other institutional capitalists possess 13.36% of the firm’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which takes part in the identification as well as advancement of oncology therapeutics. It concentrates on uncovering as well as developing small molecule drug prospects to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a complimentary copy of the Zacks research record on Onconova Therapeutics (ONTX).

For more details concerning research offerings from Zacks Investment Research, browse through Zacks.com.

This instantaneous information alert was produced by narrative science technology and monetary data from Market in order to provide readers with the fastest as well as most accurate reporting. This tale was examined by Market’s editorial team before magazine. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS NOW?

Prior to you consider Onconova Therapeutics, you’ll want to hear this.

Market keeps track of Wall Street’s premier as well as ideal performing research analysts and the stocks they suggest to their clients daily. Market has recognized the 5 stocks that top experts are quietly murmuring to their clients to purchase currently before the more comprehensive market catches on … and also Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” ranking amongst analysts, top-rated analysts believe these 5 stocks are better buys.